Meiji And Dong-A Start European Ustekinumab Trial
Dosing Of Phase I Subjects Underway
A Phase I study will compare the pharmacokinetics, safety and tolerability of Meiji and Dong-A’s DMB-3115 ustekinumab biosimilar candidate against Janssen’s Stelara reference psoriasis and Crohn’s disease brand.
You may also be interested in...
Samsung Bioepis Pushes Stelara Rival Into Phase I
Samsung Bioepis has announced that its SB17 proposed biosimilar ustekinumab rival to Janssen’s $7.7bn Stelara brand has moved into Phase I trials.
Celltrion Keeps Pace With Ustekinumab Rivals
Celltrion is looking to keep its ustekinumab biosimilar program in step with those of rival developers, after announcing the start of Phase III trials for its CT-P43 candidate.
Bio-Thera Kicks Off Ustekinumab Trial
China’s Bio-Thera solutions has announced the start of Phase I trials for its ustekinumab biosimilar. The project is one among several potential rivals to Stelara in the works from a host of developers.